Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
22 results
- D1.340 - Attack burden and patient-reported outcomes in adults with hereditary angioedema: associations with quality of life, pain, and coping strategies
- D1.337 - Long-Term Safety, Tolerability, and Effectiveness of Berotralstat in Hereditary Angioedema: Interim Analysis of the APeX-N Post-Authorization Study
- D1.339 - Renal and urinary tract disorders in inborn errors of immunity
- D1.341 - Severe Atopic Features with Prematurity and Ichthyosis: Ichthyosis Prematurity Syndrome
- D1.342 - Case Report: Off-Label Dosage of Berotralstat in Hereditary Angioedema
- D1.343 - Common Variable Immunodeficiency Associated Enteropathy: A Single-Center Experience
- D1.344 - Hidden Immunodeficiency in Adult Bronchiectasis: Lymphocyte Subsets, Humoral Defects, and Genetic Findings
- D1.346 - Clinically significant gastrointestinal endoscopic findings in asymptomatic patients with common variable immunodeficiency
- D1.347 - Lanadelumab in Children with Hereditary Angioedema Aged 2 to
D3.157 - Clinical characteristics and associated factors of persistent asthma in preschool children with wheezing in a tropical region
D3.165 - Phase 1 study of CDX-622, a bispecific antibody targeting TSLP and mast cells via stem cell factor
D3.155 - Th2–Th17 immune shift following dupilumab therapy
D3.160 - Study of the allergic sensitization profile in asthmatic patients consulting at ignace deen university hospital, conakry
D3.164 - Early and Sustained Effect of Zumilokibart (APG777) in Atopic Dermatitis and Asthma: 16-Week Results from the Phase 2 APEX Study in Moderate-to-Severe AD and a Phase 1b Study in Mild-to-Moderate Asthma
D3.213 - Sustained effectiveness of the 300 IR house dust mite sublingual tablet over 2 treatment years in a real-world data setting – results of a non-interventional study
D3.198 - Challenges of using clinical scores as primary endpoints in allergology trials
D3.199 - Severe systemic allergic reaction following violation of elimination diet in a patient with sensitization despite achieved remission on allergen-specific immunotherapy
D3.200 - Broad profile of olive pollen sensitisation as a key factor in immunotherapy failure
D3.201 - Subcutaneous immunotherapy with a depigmented cat allergoid is safe in patients with cat allergy and beneficial for mental health in adolescents
D3.205 - Two-year Outcomes of Multiple Low-Dose Oral Immunotherapies for combination of Tree Nuts or Peanut for Severe Allergy Patients
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download